Related Experiment Videos
Inflammasome-autophagy crosstalk in the tumor microenvironment
Pratyasha Mahadani1, Sushmita Patra1, Birija Sankar Patro2
1Cancer and Cell Death Laboratory, Department of Life Science, National Institute of Technology Rourkela, Sundergarh, Odisha, 769008, India.
Abstract:
The NLRP3 inflammasome has emerged as a critical sensor of cellular stress within the tumor microenvironment (TME), where its context-dependent activation can exert paradoxical effects on tumor progression and antitumor immunity. Diverse tumor-associated stressors, including mitochondrial dysfunction, reactive oxygen species (ROS), mitochondrial DNA (mtDNA) release, and cGAS-STING signaling, converge on NLRP3 activation, promoting caspase-1-dependent cytokine maturation and gasdermin D (GSDMD)-mediated pyroptosis. However, persistent or dysregulated inflammasome signaling may instead establish an immunosuppressive TME by modulating myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), and immune checkpoint responses, thereby facilitating tumor immune escape and progression. A key emerging dimension of this regulatory network is the bidirectional crosstalk between NLRP3 signaling and autophagy, particularly mitochondria-selective mitophagy. Autophagic clearance of damaged mitochondria can restrain inflammasome activation by limiting mitochondrial danger signals, whereas inflammasome-driven inflammatory and metabolic remodeling can reciprocally reshape autophagic responses. This review integrates these traditionally studied pathways into a unified NLRP3-autophagy-mitochondrial stress axis and examines how its stage-, cell-, and context-dependent regulation determines tumor fate. We further critically evaluate pharmacological modulators targeting NLRP3 and autophagy, highlighting opportunities for dual-targeting strategies to simultaneously modulate tumor-intrinsic stress responses and tumor-extrinsic immunity. Overall, defining this mechanistic interface may uncover actionable vulnerabilities and provide a framework for developing context-specific combination therapies that enhance anticancer efficacy.